Dr. Skyler's career in diabetes spans over four decades, where his research interests have concentrated in clinical aspects of diabetes, particularly improving the care of Type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune intervention.
Sentiment: Strong Buy
Wow, that sure puts to bed those claims about Afrezza only likely to be used in 5% to 10% of the prandial insulin cases. That never made any sense to me, and I always figured that common sense would dictate at least a 30% capture within a few years of commercial availability.
For the science, what I would do is look at all the studies MNKD has conducted all of which met their endpoints to my knowledge.
for anecdotal evidence, I'd look to Afrezzauser's posts and to Dr. Skyler's video and another study I briefly read about from the diabetes research center at UC Santa Barbara. The researcher at UC Santa Barbara was conducting studies using Afrezza in conjunction with exercise and described the results as "very impressive" to the interviewer. Both UC Santa Barbara and the Diabetes Research Institute are very big into research on an artificial pancreas or a cure for diabetes through an implantable "biohub." So, these guys are quite knowledgeable about diabetes.
Unlike people in this board who simply make it up as they go along then tell you they were right, these are people who have worked with Afrezza and various other methods of treating diabetes, and they all seem to have ringing endorsements for Afrezza.